Britain and America have hammered out a key trade agreement that will maintain no levies on UK pharmaceutical exports entering the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost spending on drugs through the public health system. This commitment guarantees that duties on these key goods will be held at nothing for a timeframe of the next three years.
This agreement follows earlier threats to dramatically increase tariffs on branded drug products, with increases floated up to double the cost.
"This agreement with the United Kingdom reinforces the global environment for new treatments and establishes much-needed balance to U.S.–U.K. medicine commerce," a release said.
Trade Significance
Drugs constitute one of the the United Kingdom's most significant exports to the United States, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period leading up to the third quarter, the UK sold pharmaceutical products totaling billions to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This deal safeguards work, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for medical research," a government official remarked.
Key British Pledges
The deal includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a aim to increase total health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, refunds exceeded twenty percent.
Broader Context
The pact takes place against a protracted row between the drug companies and the British authorities over drug pricing and approval rates.
These tensions were heightened by arguments that US patients were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its spending on drugs had decreased as a percentage of its total funding over the previous ten-year period.
